Catalent Increases Stake in Redwood Bioscience
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has announced that based on compelling data generated by the SMARTag ADC platform, it has increased its minority investment in Redwood Bioscience.
The proprietary SMARTag precision protein-chemical engineering platform and novel toxin-linker technologies developed by Redwood enable the generation of homogeneous antibody-drug conjugates (ADCs) engineered to enhance potency, safety and stability.
Catalent announced in April 2013 that it had acquired an exclusive licence to market the SMARTag technology and has subsequently collaborated with Redwood for the ongoing development and marketing of the technology. As part of the collaboration, Catalent took a minority equity stake in Redwood, which may increase over time up to a potential acquisition.
Redwood’s novel, site-specific protein modification and linker technologies enable the generation of homogenous bioconjugates engineered to improve performance and ease of manufacturing. Combined with Catalent’s proprietary GPEx cell line expression system, its recently completed state-of-the-art biomanufacturing Center of Excellence in Madison, Wisconsin and broad range of analytical and fill-finish services, the latest investment marks a further expansion of Catalent’s capabilities to help customers develop more and better biologic treatments.
“The potential that we initially identified in the SMARTag technology has been borne out by the successful achievement of in vivo and in vitro proof of concept milestones, leading to our next phase of investment,” commented Barry Littlejohns, President, Advanced Delivery Technologies. He added: “These studies have further illustrated that our ongoing collaboration with Redwood will offer significant and differentiating value to our growing number of customers looking to develop next-generation ADC therapies.”
Redwood’s novel protein conjugation and linker technologies overcome the limitations associated with conventional protein chemistries that produce heterogeneous products with variable conjugate potency, toxicity and stability. The SMARTag technology enables site-specific, programmable drug-protein conjugation and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering. The programmability afforded by Redwood’s technology provides control over conjugate configuration, generating ADCs with optimal efficacy, safety and stability. The Redwood platform also enables the use of proprietary conjugation chemistry that reduces systemic drug loss and increases targeted potency. Redwood has developed an array of cytotoxin-linkers utilizing this novel chemistry, which are designed for optimal stability.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance